University of Pennsylvania Health System
Welcome,         Profile    Billing    Logout  
 98 Trials 
62 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brem, Steven
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

Available
N/A
US
DCVax-L
Northwest Biotherapeutics
GBM, Glioblastoma Multiforme
 
 
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Derk, Chris
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
07/27
07/27
Dixit, Sanjay
ARISTOCRAT, NCT05629702: Blinded Trial of Temozolomide +/- Cannabinoids

Recruiting
2
234
Europe
Nabiximols, Sativex, Temozolomide, Nabiximols-matched placebo
University of Birmingham, University of Leeds, The Brain Tumour Charity, Jazz Pharmaceuticals
Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
02/26
02/27
Reddy, K Rajender
APACHE, NCT03702920 / 2016-001787-10: Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Recruiting
3
380
Europe, US
SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Acute-On-Chronic Liver Failure
10/26
10/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Recruiting
N/A
2500
US
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Exact Sciences Corporation
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
01/25
04/26
Bloom, Roy
PTAAK, NCT03841097: Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants

Recruiting
4
60
US
Extended Release Tacrolimus Tablets, LCPT, Envarsus XR®, Immediate Release Tacrolimus Capsule, IR-TAC, Prograf®
Roy D. Bloom, MD, Veloxis Pharmaceuticals
Kidney Transplant; Complications
03/25
09/25
SAFE KIDNEY II, NCT05769582: Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

Recruiting
2/3
180
US
Anti-BK polyomavirus (AntiBKV)
Memo Therapeutics AG
BK Viremia; BKV DNAemia
11/24
11/24
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Active, not recruiting
N/A
4000
US
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
CareDx
Kidney Transplant Rejection
06/25
12/25
Bleier, Joshua
NCT05414955: Boom-IBD Clinical Trial

Active, not recruiting
N/A
40
US
Neuromodulation
Boomerang Medical
IBD
12/24
12/24
NCT04940611: A Study of Surgical Interventions in Fistulizing Conditions

Active, not recruiting
N/A
750
Europe, Canada, US, RoW
Takeda
Crohns Disease, Fistula, Rectovaginal Fistula, Complex Perianal Fistula, Complex Cryptoglandular Fistula
05/26
05/26
Martin, Lainie P
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting
1/2
523
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
05/23
10/24
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
STRO-002-GM1, NCT03748186: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Completed
1
136
Europe, US
STRO-002
Sutro Biopharma, Inc.
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/24
06/24
Goldberg, Lee
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
RECOVER-HF, NCT06552637: Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

Not yet recruiting
N/A
270
NA
Synchronized Diaphragmatic Stimulation, Asymptomatic Diaphragmatic Stimulation, SDS, ADS, VisONE SDS
VisCardia Inc., Clinical Accelerator Ltd., Duke Clinical Research Institute
Heart Failure With Reduced Ejection Fraction
07/27
12/27
rēST Study, NCT03884660: Remedē System Therapy Study

Recruiting
N/A
500
Europe, US
remede System
Respicardia, Inc.
Central Sleep Apnea
06/27
06/32
Bella, Paolo Della
LESS-VT, NCT03490201: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

Completed
N/A
592
Europe, US, RoW
Market Approved RF Ablation System, FlexAbility SE Ablation Catheter
Abbott Medical Devices
Ventricular Tachycardia
04/24
04/24
BIO|STREAM HF, NCT03366545: Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

Recruiting
N/A
3000
Europe, Japan, RoW
Cardiac Resynchronization Therapy (CRT)
Biotronik SE & Co. KG
Heart Failure
03/26
03/26
Margulies, Kenneth
NCT02123706: A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology

Recruiting
2a
20
US
Human Allogeneic Mesenchymal Stem Cells, Mesenchymal Stem Cells, Marrow Stromal Cells, Placebo, Lactated Ringer's Solution
Stemedica Cell Technologies, Inc., CardioCell, LLC; A Stemedica Company
Non-ischemic Heart Failure
06/16
06/16
NCT04956809: Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

Completed
2
3
US
Dapagliflozin 10Mg Tab, Placebo
University of Pennsylvania, Amgen
HFrEF
06/23
06/23
EMAS-HF, NCT05885607: Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure

Enrolling by invitation
N/A
40
US
University of Pennsylvania, Amgen
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
06/25
08/25
Desai, Nimesh
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
TAMBE, NCT05442489: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms

Approved for marketing
N/A
US
GORE Excluder Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aneurysm
 
 
SSB 11-02, NCT02777528: Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)

Active, not recruiting
N/A
150
Japan, US
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta, Lesion
03/24
03/28
PANTHER, NCT04545502: Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

Recruiting
N/A
2000
Europe, Canada, US
Gelsoft Plus Vascular Graft, Gelsoft Plus, Vascular Bypass Graft, Gelsoft Plus Extra Anatomical, Cardiovascular Patch, Gelseal Patch, Gelsoft Patch, Thinwall Patch, Cardiovascular Fabrics, Gelweave Vascular Graft, Gelweave, Gelweave Valsalva Vascular Graft, Gelweave Valsalva
Vascutek Ltd.
Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
01/26
01/33
TAMBE, NCT03728985: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Active, not recruiting
N/A
102
Europe, US
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aortic Aneurysm
01/23
09/26
Messe, Steven
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Terminated
3
535
Europe, Canada, Japan, US, RoW
BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo
Remedy Pharmaceuticals, Inc.
Brain Edema, Stroke, Acute
08/23
08/23
ReMEDy2, NCT05065216: Treatment of Acute Ischemic Stroke ( Trial)

Recruiting
2/3
728
US
Recombinant human tissue kallikrein, DM199, Placebo for DM199 Solution for Injection
DiaMedica Therapeutics Inc
Acute Stroke, Ischemic Stroke, Stroke
12/26
12/26
OSC-VTE-003, NCT05389488: OsciPulse D-dimer Efficacy Trial

Withdrawn
2
40
US
OsciPulse system, Flowtron ACS900
OsciFlex LLC, University of Pennsylvania
Venous Thromboses, Ischemic Stroke
12/22
03/23
DOMINO, NCT03023449: Diffuse Optical Monitoring with Inhaled Nitric Oxide

Active, not recruiting
2
40
US
Nitric Oxide, iNO, NO2
Steven Messe, Mallinckrodt
Stroke
07/25
07/25
NCT06477016: OsciPulse D-dimer Pilot Trial

Not yet recruiting
N/A
40
US
OsciPulse, Intermittent Pneumatic Compression
University of Pennsylvania, OsciFlex LLC
Ischemic Stroke
11/25
11/25
CHaMP, NCT05155956: Cerebral Hemodynamics and Microemboli During Placement of Relay®Branch Thoracic Stent-Graft System

Active, not recruiting
N/A
20
US
transcranial Doppler ultrasonography (TCD)
University of Pennsylvania, Bolton Medical
Thoracic Aortic Aneurysm, Thoracic Aortic Dissection, Microemboli
12/24
12/25
Cuker, Adam
KEYSTONE 1, NCT06297486: Study of a Gene Therapy Treatment for Hemophilia A

Withdrawn
3
85
US
SPK-8011, AAV-Spark200-BDD-hFVIII, Dirloctocogene samoparvovec
Spark Therapeutics, Inc.
Hemophilia A
05/27
09/35
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
08/25
05/28
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Recruiting
3
225
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo, Corticosteroids
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
04/26
12/28
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
VAYHIT3, NCT05885555: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Active, not recruiting
2
41
Europe, US, RoW
Ianalumab, VAY736
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
02/25
03/29
ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
NCT05904210: Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®

Completed
N/A
17
US
SEVENFACT®
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
05/24
05/24
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Halpern, Casey
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
DBSLOC, NCT03868670: Responsive Neurostimulation For Loss Of Control Eating

Recruiting
N/A
6
US
responsive neurostimulation
University of Pennsylvania, NeuroPace
Loss of Control Eating, Obesity, Morbid
01/25
01/25
NCT05539196: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Recruiting
N/A
60
Japan, US
Exablate Pallidotomy, Unilateral
InSightec
Movement Disorders, Neurology, Parkinsons Disease
07/29
07/29
Cohen, Debbie
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting
N/A
1400
Europe, US, RoW
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
11/26
11/29
TRIO CAP, NCT05017935: RADIANCE Continued Access Protocol

Active, not recruiting
N/A
300
US
Renal Denervation
ReCor Medical, Inc.
Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
12/28
12/28
Martin, Niels
NCT05156983 / 2021-004138-12: A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Recruiting
3
328
Europe, Canada, US
TAK-330, SOC 4F-PCC
Takeda, Takeda Development Center Americas, Inc.
Coagulation Disorder
04/28
04/28
Neubauer, Robin
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting
2
25
US
Dostarlimab, Jemperli, Niraparib, Zejula
H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline
Penile Carcinoma
11/26
11/27
NUV-868-01, NCT05252390: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Recruiting
1/2
657
US, RoW
NUV-868, Olaparib, Lynparza, Enzalutamide, Xtandi
Nuvation Bio Inc.
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
06/26
11/26
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Active, not recruiting
N/A
4000
US
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
CareDx
Kidney Transplant Rejection
06/25
12/25
Broach, Robyn
NCT03460158: Prospective Evaluation of Facial Cosmetic Procedures

Completed
4
101
US
Restylane-L®, Hyaluronic acid gel, Restylane-L® Lyft, Restylane Silk®
University of Pennsylvania, Galderma R&D
Cosmetic Techniques
02/24
05/24
ADMIRE, NCT06456554: Acellular Dermal Matrix Investigation in Breast Reconstruction

Recruiting
N/A
467
US
Acellular Dermal Matrix (Cortiva Tissue Matrix)
RTI Surgical, Bright Research Partners, MCRA
Breast Reconstruction
12/26
12/27
Percec, Ivona
NCT03460158: Prospective Evaluation of Facial Cosmetic Procedures

Completed
4
101
US
Restylane-L®, Hyaluronic acid gel, Restylane-L® Lyft, Restylane Silk®
University of Pennsylvania, Galderma R&D
Cosmetic Techniques
02/24
05/24
Jefferson, Ashlie
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
Shah, Payal D
TBCRC 048, NCT03344965: Olaparib in Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/25
12/25
Saci-IO TNBC, NCT04468061: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Hourglass Jan 2022 - Jun 2022 : Initiation of P3 trial in combination with keytruda for 1L mTNBC
Recruiting
2
110
US
Sacituzumab Govitecan, IMMU-132, Trodelvy, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Gilead Sciences, Merck Sharp & Dohme LLC
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
04/26
04/29
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
NCT04991480: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Active, not recruiting
1
390
Europe, US
ART4215, Talazoparib, Talzenna, Niraparib, Zejula
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Breast Cancer
03/25
08/25
Perrone, Jeanmarie
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial

Completed
2
2000
US
CAM2038, Buprenorphine Sublingual Product
Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
12/24
12/24
Centeno, Claire
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/24
12/26
Schneider, Rachelle
No trials found
Kilaru, Austin
No trials found
Kry, Yolanda
No trials found
Demastus, Cassandra J
No trials found
HUSSAIN, JASMINE
No trials found
Torrente, Dena
No trials found
Hamilton, Keith
No trials found
Szymczak, Julia
No trials found
Dutcher, Lauren
No trials found
Schnaubelt, Andrew
No trials found

Download Options